Dr. Jordan Garris
Claim this profileClinical Trials Jordan Garris is currently running
More about Jordan Garris
Clinical Trial Related
2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Jordan Garris has experience with
- Tremor Retrainer Software Application
Breakdown of trials Jordan Garris has run
Conversion Disorder
Conversion disorder
Functional Neurological Disorder
Functional Neurological Symptom Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jordan Garris specialize in?
Jordan Garris focuses on Conversion Disorder and Conversion disorder. In particular, much of their work with Conversion Disorder has involved treating patients, or patients who are undergoing treatment.
Is Jordan Garris currently recruiting for clinical trials?
Yes, Jordan Garris is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Jordan Garris has studied deeply?
Yes, Jordan Garris has studied treatments such as Tremor Retrainer Software Application.
What is the best way to schedule an appointment with Jordan Garris?
Apply for one of the trials that Jordan Garris is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.